You are using an older browser version. Please use a supported version for the best MSN experience.

BRIEF-Inbrx-101 Shows Favorable Safety Profile In Patients With Alpha-1 Antitrypsin Deficiency

Reuters logo Reuters 4 days ago

Oct 12 (Reuters) - Inhibrx Inc:

* INBRX-101 SHOWS FAVORABLE SAFETY PROFILE IN PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY AND DEMONSTRATES THE POTENTIAL TO ACHIEVE NORMAL ALPHA-1 ANTITRYPSIN LEVELS WITH MONTHLY DOSING

* INHIBRX INC - INTERIM RESULTS FROM PHASE 1 STUDY SHOW A FAVORABLE SAFETY AND TOLERABILITY PROFILE

* INHIBRX INC - DATA FROM SINGLE ASCENDING DOSE COHORTS AT 10, 40, 80 AND 120 MG/KG REVEALED POTENTIAL TO ACHIEVE NORMAL AAT LEVELS WITH MONTHLY DOSING

* INHIBRX INC - DATA FROM FIRST MULTIPLE ASCENDING DOSE COHORT AT 40 MG/KG IV EVERY THREE WEEKS SHOWED EXPECTED ACCUMULATION OF FUNCTIONAL AAT LEVELS

* INHIBRX INC - NO DRUG-RELATED SEVERE OR SERIOUS ADVERSE EVENTS AT DOSES UP TO AND INCLUDING 120 MG/KG SINGLE DOSE AND 80MG/KG MULTI-DOSE Source text for Eikon: Further company coverage:

AdChoices
AdChoices

View the full site

image beaconimage beaconimage beacon